Image-guided interstitial high-dose-rate brachytherapy for dose escalation in the radiotherapy treatment of locally advanced lung cancer: A single-institute experience.
High-dose-rate
Interstitial brachytherapy
Locally-advanced NSCLC
Multimodality treatment
Journal
Brachytherapy
ISSN: 1873-1449
Titre abrégé: Brachytherapy
Pays: United States
ID NLM: 101137600
Informations de publication
Date de publication:
Historique:
received:
22
03
2019
revised:
02
07
2019
accepted:
06
08
2019
pubmed:
11
9
2019
medline:
21
4
2020
entrez:
11
9
2019
Statut:
ppublish
Résumé
To evaluate the clinical outcome after CT-guided interstitial high-dose-rate (HDR) brachytherapy for dose escalation in the radiotherapy treatment of inoperable locally advanced non-small-cell lung cancer (NSCLC). From 2005 to 2015, 16 patients with unresectable NSCLC were treated. Median age was 65.7 years (range, 52-86). The median tumor volume was 95.3 cm After a median followup of 12.5 months, median overall survival and local control was 12.9 and 24.9 months, respectively. The corresponding median overall survival and local control rates at 1, 2, and 3 years were 56.2%, 37.5%, and 12.5% as well as 68.9%, 57.4%, and 43%, respectively. Apart from one Grade 1 cough episode persisting for 1 week and one patient developing a minor hemopneumothorax requiring no postprocedural drainage, no other adverse events were recorded. CT-guided interstitial HDR brachytherapy is a safe modality for radiation dose escalation which may play a role in the definitive radiotherapy treatment of locally advanced NSCLC.
Identifiants
pubmed: 31500935
pii: S1538-4721(19)30117-5
doi: 10.1016/j.brachy.2019.08.001
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
829-834Informations de copyright
Copyright © 2019 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.